AstraZeneca (LSE:AZN) said its wholly owned subsidiary, AstraZeneca Finance, priced four tranches of Eurobonds totalling €2.55 billion on 24 August.
The pharmaceutical group, which develops and sells prescription medicines in oncology, rare disease and biopharmaceuticals across more than 125 countries, said the offering aligns with its long-term funding strategy.
The notes span maturities from 2030 to 2038.
A €700 million tranche carries a 3.402% coupon and matures on 1 March 2030, whilst a €600 million tranche carries a 3.652% coupon maturing on 1 September 2032, and a €500 million tranche carries a 3.923% coupon maturing on 1 September 2035.
The largest tranche, of €750 million, carries a 4.169% coupon and matures on 1 September 2038.
News Intelligence what this means for the company
AstraZeneca Finance priced €2.55 billion of Eurobonds across four tranches maturing 2030–2038, with coupons ranging from 3.4% to 4.2%, for general corporate purposes. The timing follows a period of elevated net debt—which stood at $26.9bn at end-June 2026—and comes amid active pipeline progress in oncology and rare disease, anchoring the company's long-term funding strategy.
The bond issuance signals confidence in AstraZeneca's cash generation and refinancing access at moderate rates, consistent with its stated capital allocation framework. At €2.55bn against H1 2026 revenue of $30.67bn, the raise is modest in scale and does not materially alter the company's leverage profile or strategic flexibility.
Insights assembled by AI. Editor-reviewed and grounded in tickstock’s coverage and proprietary knowledge graph.
Content is for informational purposes only, not financial advice.
